-
公开(公告)号:ES2238681T3
公开(公告)日:2005-09-01
申请号:ES95922635
申请日:1995-06-21
Applicant: CELLTECH R&D LTD
Inventor: WARRELLOW GRAHAM JOHN , BOYD EWAN CAMPBELL , ALEXANDER RIKKI PETER
IPC: A61K31/395 , A61K31/44 , A61K31/4433 , A61P43/00 , C07C1/26 , C07C1/32 , C07C15/02 , C07C15/12 , C07C17/263 , C07C25/02 , C07C25/18 , C07C43/20 , C07C49/753 , C07C57/30 , C07C59/64 , C07C69/76 , C07C291/04 , C07C311/15 , C07D213/30 , C07D213/89 , C07D401/00 , C07D405/00 , C07D409/00 , C07D409/12 , C07D411/00 , C07D413/00 , C07D417/00 , C07D471/04 , C07D521/00
Abstract: SE DESCRIBEN COMPOSICIONES DE FORMULA GENERAL (1), FORMULA EN DONDE =W- ES (1) =C(()Y())- DONDE Y ES UN ATOMO DE HALOGENO, O UN ALQUILO O UN GRUPO -XR{SUP,A} DONDE X ES -O-, S(()O()){SUB,M}- [DONDE M ES CERO O UN ENTERO DE VALOR 1 O 2], O -N(()R{SUP,B}())- [DONDE R{SUP,B} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO] Y R{SUP,A} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO O, (2) =N-; L ES (1) UN GRUPO -C(()R())=C(()R{SUP,1}())(()R{SUP,2}()) O [[]-CH(()R())[]]{SUB,N}CH(()R{SUP,1}())(()R{SUP,2}()); ES (2) UN GRUPO -(()X{SUP,A}()){SUB,N}ALK''AR'', O ALK''X{SUP,A}AR''; O ES (3) X{SUP,A}R{SUP,1}; Z ES UN GRUPO (A), (B), (C) O (D) EN DONDE AR ES UN GRUPO ARILO MONOCICLICO O BICICLICO QUE CONTIENE OPCIONALMENTE UNO O MAS HETEROATOMOS SELECCIONADOS DE ATOMOS DE OXIGENO, AZUFRE O NITROGENO; Z{SUP,1} ES UN GRUPO NR{SUP,12}C(()O())- [DONDE R{SUP,12} ES UN ATOMO DE HIDROGENO O UN ALQUILO OPCIONALMENTE SUSTITUIDO O UN GRUPO (()ALK()){SUB,T}AR], -C(()O())NR{SUP,12-}, -NR{SUP,12}C(()S())-, -C(()S())NR{SUP,12-}, -C=C-, -NR{SUP,12}SO{SUB,2-}, O SO{SUB,2}NR{SUP,12}; ALK ES UNA CADENA DE ALQUILO RECTA O RAMIFICADA OPCIONALMENTE SUSTITUIDA POR UN ATOMO O GRUPO X; T ES CERO O UN ENTERO DE VALOR 1, 2 O 3; R{SUP,3} ES UN ATOMO DE HIDROGENO O DE FLUOR O UN GRUPO ALQUILO RECTO O RAMIFICADO OPCIONALMENTE SUSTITUIDO O UN GRUPO OR{SUP,11} [DONDE R{SUP,11} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO, ALQUENILO, ALCOXIALQUILO, ALCANOILO, FORMILO, CARBOXAMIDA O TIOCARBOXAMIDA OPCIONALMENTE SUSTITUIDO]; R{SUP,4} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO, -CO{SUB,2}R{SUP,8}, CSNR{SUP,9}R{SUP,10, -CN, -CH{SUB,2}CN, O (()CH{SUB,2}()){SUB,T}AR OPCIONALMENTE SUSTITUIDO DONDE T ES CERO O UN ENTERO DE VALOR 1, 2 O 3 Y AR ES UN GRUPO ARILO MONOCICLICO O BICICLICO QUE CONTIENE OPCIONALMENTE UNO O MAS HETEROATOMOS SELECCIONADOS ENTRE ATOMO DE OXIGENO, AZUFRE O NITROGENO; CON TAL DE QUE CUANDO L SEA UN GRUPO DE TIPO (2) O (3), ENTONCES Z SEA UN GRUPO DEL TIPO (A) O TIPO (B) EN EL QUE R{SUP,4} ES UN GRUPO (()CH{SUB,2}()){SUB,T}AR; R{SUP,5} ES UN GRUPO (()CH{SUB,2}()){SUB,T}AR; R{SUP,6} ES UN ATOMO DE HIDROGENO O DE FLUOR, O UN ALQUILO OPCIONALMENTE SUSTITUIDO O UN GRUPO CO{SUB,2}R{SUP,8}, -CONR{SUP,9}R{SUP,10}, -CSNR{SUP,9}R{SUP,10}, -CN O -CH{SUB,2}CN; R{SUP,7} ES UN ATOMO DE HIDROGENO O DE FLUOR, UN GRUPO ALQUILO RECTO O RAMIFICADO OPCIONALMENTE SUSTITUIDO, O UN GRUPO OR{SUP,C} DONDE R{SUP,C} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO O ALQUENILO OPCIONALMENTE SUSTITUIDO, UN GRUPO ALCOXIALQUILO, ALCANOILO, FORMILO, CARBOXAMIDA O TIOCARBOXAMIDA; Y LAS SALES, SOLVATOS, HIDRATOS, PROFARMACOS Y N-OXIDOS DE LOS MISMOS. COMPOSICIONES DE ACUERDO CON LA INVENCION SON INHIBIDORES DE FOSFODIESTERASA TIPO IV Y SON UTILES EN LA PROFILAXIS Y TRATAMIENTO DE ENFERMEDADES COMO EL ASMA DONDE ESTAN PRESENTES RESPUESTAS INFLAMATORIAS O ESPASMOS MUSCULARES NO DESEADOS.
-
公开(公告)号:PL373277A1
公开(公告)日:2005-08-22
申请号:PL37327703
申请日:2003-05-02
Applicant: CELLTECH R&D LTD
IPC: C07K16/18 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N15/13 , C12N15/63 , C12P21/00 , C12N15/85 , C12N5/10
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
公开(公告)号:GB0512402D0
公开(公告)日:2005-07-27
申请号:GB0512402
申请日:2005-06-17
Applicant: OXFORD INSTR MOLECULAR BIOTOOL , UNIV DURHAM , CELLTECH R&D LTD
Abstract: A method of providing magnetised particles at a location using particles which can be switched between magnetic and non-magnetic states by exposure to a suitable magnetic field. The method comprises conveying the particles in their non-magnetic state to the location; and then exposing the particles to the suitable magnetic field so that they switch to their magnetic state.
-
公开(公告)号:AU2004305291A1
公开(公告)日:2005-07-07
申请号:AU2004305291
申请日:2004-12-14
Applicant: CELLTECH R&D LTD
Inventor: NORMAN TIMOTHY JOHN
IPC: A61K47/48
Abstract: Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by means of hydrolytically stable linkages.
-
-
公开(公告)号:CA2544920A1
公开(公告)日:2005-06-09
申请号:CA2544920
申请日:2004-11-16
Applicant: CELLTECH R&D LTD
Inventor: RAPECKI STEPHEN EDWARD , MEAD RICHARD JAMES , ROBINSON MARTYN KIM , CHRISTIE MARK IAN
IPC: A61K39/395 , A61K47/48 , A61P37/00 , C07K16/24
-
公开(公告)号:PL370344A1
公开(公告)日:2005-05-16
申请号:PL37034402
申请日:2002-10-10
Applicant: CELLTECH R&D LTD
Inventor: POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号:AU2004285339A1
公开(公告)日:2005-05-12
申请号:AU2004285339
申请日:2004-10-22
Applicant: CELLTECH R&D LTD
Inventor: BURGESS NICOLA ANNE
-
公开(公告)号:CL2004000259A1
公开(公告)日:2005-04-15
申请号:CL2004000259
申请日:2004-02-12
Applicant: CELLTECH R&D LTD
Inventor: LAWSON ALSTAIR DAVID GRIFFITHS
-
公开(公告)号:AU2004270929A1
公开(公告)日:2005-03-17
申请号:AU2004270929
申请日:2004-09-02
Applicant: CELLTECH R&D LTD
Inventor: REEKS DOMINIC GAMBIER , SEHDEV MUKESH , GLOVER DAVID JOHN
Abstract: The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E. coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an inducible system, which method comprises: a) providing an E. coli host cell culture b) changing the growth rate of the E. coli host cells c) inducing expression of the recombinant protein wherein steps (b) and (c) can be performed in any order or simultaneously; and subsequently d) determining the yield of recombinant protein in the culture supernatant and the E. coli host cell periplasm e) comparing the yield determined in step (d) with the yield determined when at least one other growth rate has been used in step (b) f) selecting a growth rate from the comparison made in step (e) in which the partitioning of the recombinant protein between the supernatant and the periplasm is most suited to the primary recovery of the recombinant protein.
-
-
-
-
-
-
-
-
-